NYC Healthcare News



Excess levels of a protein associated with TNF may produce cognitive decline: Studies

September 20, 2015

Q Therapeutics is developing a proprietary glial cell-based therapeutic (Q-Cells?) for treatment of neurodegenerative diseases. Dr. Walczak's work targeting demyelinating conditions such as multiple sclerosis (MS), transverse myelitis, and spinal cord injury represents a significant class of diseases of the central nervous system for Q-Cells. Q is also conducting preclinical studies to enable it to submit an IND to use Q-Cells to treat patients with the neurodegenerative disease amyotrophic lateral sclerosis (ALS, also called Lou Gehrig's Disease). The work in ALS is being conducted in collaboration with Nicholas Maragakis, M.D., at Johns Hopkins University, funded in part under an NIH U01 grant and a separate grant from MSCRF.

Q Therapeutics President and CEO, Deborah Eppstein, Ph.D., welcomed the opportunity to expand its collaborative studies with Dr. Walczak on use of Q-Cells in diseases involving deficiencies in myelination. "We believe that Q-Cells have applicability to several different types of central nervous system diseases. We look forward to joining Drs. Walczak and Bulte (Director, CIS ICE) on this important project to study the efficacy of glial cells derived from these several sources, broadening use of Q-Cells for treatment of demyelinating diseases."

Source Q Therapeutics, Inc.